1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU HTA Regulation: Tight Deadlines & The Future Of Collaboration

 
• By Francesca Bruce

The next stage of collaboration on health technology assessments in the EU after the new HTA Regulation is implemented is unlikely to venture into health economics, instead it will likely focus on working with international bodies outside the union.

Tight Timelines will not derail implementation of EU HTA Regulation • Source: Shutterstock

Despite industry anxieties, tight timelines for finalizing the methodologies underpinning the Health Technology Assessment Regulation will not mean a rushed or unfinished system for the new EU-level joint clinical assessment (JCA) system, said Niklas Hedberg, co-chair of the new HTA Coordination Group established by the regulation.

In an interview with the Pink Sheet, Hedberg assured industry that HTA bodies and the European Commission are working to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EU Industry Proposes 3-Basket Strategy To Phase Out Animal Testing

 
• By Eliza Slawther

A “basket approach” to phasing out animal testing could help identify areas where “moonshot” research is required to implement new approach methodologies, according to EU industry federation EFPIA.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 
• By Neena Brizmohun

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.

Consumer Groups Have A ‘Radical Transparency’ List For US FDA’s PDUFA VIII

 
• By Sarah Karlin-Smith

Development of the user fee commitment letter largely takes place behind closed doors between industry and FDA. Outside groups see the upcoming negotiation cycle as a chance to change this and other agency information blocks by reminding Commissioner Makary of his commitment to transparency.